CA-CEPTON-TECHNOLOGIES
A new technology partnership is set to transform road tolling for both providers and motorists alike by utilizing the latest advances in lidar technology and data analytics.
Cepton Technologies, Inc. has collaborated with industrial perception and machine learning experts, MechaSpin, to develop a lidar-based solution that produces detailed 3D classification of vehicles in real time for automated tolling applications. This next-generation solution combines Cepton’s Sora-P60 with MechaSpin’s MSx software to enable immediate profiling and classification of vehicles at highway speeds in a wide range of weather and lighting conditions.
Traditional tolling systems often depend on physical infrastructure to reduce vehicle speed, or tollbooths to allow for manual processing, which can cause congestion and frustration amongst motorists. Advanced systems that allow for faster tolling, however, are often subject to abuses such as leakage, while road-based sensors often fail due to wear and tear.
Cepton and MechaSpin’s solution addresses such challenges by eliminating the need for physical infrastructure while providing accurate data, such as vehicle velocity, size and axle count, in a format that can be integrated with other sensor, data capture and billing systems. At the same time, the hardware is designed for aerial installation and contains minimal moving parts, reducing the likelihood of failure.
Neil Huntingdon, Cepton’s VP of Business Development, said: “Our partnership with MechaSpin is founded on both businesses’ deep understanding of the unique and powerful capabilities of lidar, especially when it is teamed with problem solving software solutions.
“We believe that this partnership will bring major innovations to the tolling industry. Our Sora-P60 lidar delivers an unrivalled scan speed at 380Hz, making it possible to profile vehicles as they pass at highway speeds. Our partnership with MechaSpin will allow for faster, more accurate and lower cost management of our transport infrastructure as the number of vehicles continues to grow globally.”
Danny Kent, PhD, MechaSpin’s President, added: “The tolling industry lacks an integrated end-to-end solution for deploying 3D lidar for vehicle classification and tracking. MechaSpin and Cepton have partnered to deliver a solution for this need. Cepton's lidar technology coupled with MechaSpin's MSx Processing Engine offers a robust solution for tolling, intermodal and other transportation industry applications.”
Cepton will be showcasing its state-of-the-art lidar solutions at the 26th ITS World Congress in Singapore from October 21 to October 25, 2019. Please visit Cepton’s booth (B04) for more information or to arrange a live demo.
Founded in 2016 by Dr. Jun Pei and Dr. Mark McCord, Cepton is the only company in the industry to ship high-performance and low-cost lidar sensors directly to customers.
Lidar technology is not new, however its usage across industries is growing thanks to its power efficient, environmentally agnostic qualities. Like bats, which use sound waves during echolocation to measure distances and determine the location of an object, lidar utilises light waves from a laser to send a pulse of light and measure the amount of time it takes to reflect back from objects, making it possible to measure the distance between them. Since the speed of light is constant, distance can be easily calculated by measuring the time it takes for the beam to return.
Lidar systems use these pulses to create three-dimensional point clouds of their surrounding area, providing cars and other smart machines with highly accurate perception data to autonomously navigate.
Cepton's Micro Motion Technology (MMT™) is unique to the industry. Unlike traditional beam-steering technologies, such as spinning lidar and micro-electronical mechanical systems (MEMS), Cepton’s MMT architecture enables a mirrorless, frictionless and rotation-free system to increase the durability, reliability and manufacturability of the product, while delivering industry-leading range and resolution for highly accurate 3D sensing.
For more information about Cepton Technologies Inc., visit www.cepton.com
For more information about MechaSpin visit www.mechaspin.com
About Cepton Technologies, Inc.
Cepton Technologies, Inc. is a 3D sensing solutions provider shipping state-of-the-art lidar products for the automotive, security, transport infrastructure, industrial, IoT and mapping markets.
Founded in 2016 and led by industry veterans with deep experience in lidar and advanced imaging, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions for the automotive industry and beyond.
Cepton’s patented lidar technology delivers outstanding detection range and resolution, reliability and affordability, to enable perception for the fast-growing market for autonomous and smart machines.
For more information, visit: http://www.cepton.com/ .
Cepton is headquartered in San Jose, California, USA.
It also has offices in Germany, Canada and UK.
About MechaSpin
MechaSpin is an experienced Systems Integrator and Solution Provider dedicated to using lidar technology to make the world safer, more efficient and more productive. MechaSpin’s MSx Processing Engine provides advanced signal processing and machine learning algorithms for 3D lidar data.
Founded in 2010, MechaSpin is led by engineers that started their careers as participants in the DARPA Grand Challenges, fielding lidar technology for autonomous robotic vehicles. MechaSpin’s team is focused on bringing sensors, algorithms and technologies from the self-driving car industry into industrial markets such as material handling, tolling, port and terminal, intermodal, and more.
For more information, visit: http://www.mechaspin.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005006/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom